US 12,029,746 B2
Oral composition
Yusuke Kobayashi, Meguro-ku (JP); Yuichi Shimoda, Ichikawa (JP); Hiroko Uchida, Koto-ku (JP); Sho Aida, Yokohama (JP); and Shun Sakoda, Soka (JP)
Assigned to KAO CORPORATION, Tokyo (JP)
Appl. No. 17/254,674
Filed by KAO CORPORATION, Tokyo (JP)
PCT Filed Jun. 20, 2019, PCT No. PCT/JP2019/024495
§ 371(c)(1), (2) Date Dec. 21, 2020,
PCT Pub. No. WO2019/244976, PCT Pub. Date Dec. 26, 2019.
Claims priority of application No. 2018-118569 (JP), filed on Jun. 22, 2018; and application No. 2018-209228 (JP), filed on Nov. 6, 2018.
Prior Publication US 2021/0220382 A1, Jul. 22, 2021
Int. Cl. A61K 31/7048 (2006.01); A23L 27/00 (2016.01); A23L 27/10 (2016.01); A23L 27/30 (2016.01); A23L 33/00 (2016.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/68 (2006.01); A61K 31/11 (2006.01); A61K 31/352 (2006.01)
CPC A61K 31/7048 (2013.01) [A23L 27/10 (2016.08); A23L 27/33 (2016.08); A23L 27/88 (2016.08); A23L 33/30 (2016.08); A61K 9/0058 (2013.01); A61K 9/16 (2013.01); A61K 9/20 (2013.01); A61K 31/11 (2013.01); A61K 31/352 (2013.01)] 15 Claims
 
1. An oral composition, comprising the following components (A), (B), (C), and (D):
(A) non-polymer catechins;
(B) rutin;
(C) astragalin; and
(D) vanillin,
wherein a content of the component (A) in solids is from 2 mass % to 50 mass %,
wherein a content of the component (D) in solids is from 0.05×10−4 mass % to 100×10−4 mass %,
wherein a mass ratio of the component (B) to the component (A), [(B)/(A)], is from 0.05×10−2 to 50×10−2, and
wherein a mass ratio of the component (C) to the component (A), [(C)/(A)], is from 7.0×10−3 to 50×10−3.